Old Web
English
Sign In
Acemap
>
Paper
>
Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation.
Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation.
2021
Daniel Morgensztern
Ramaswamy Govindan
Keywords:
Oncology
Consolidation (soil)
Mutant
Durvalumab
Internal medicine
standard therapy
Stage (cooking)
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
17
References
0
Citations
NaN
KQI
[]